Date: Thursday, December 3, 2015
Location: Scaletta Ristorante, 50 West 77th street, New York, NY
Speaker: Michael Nailor, Pharm.D.
Clinical Specialist-Infectious Diseases, Hartford Hospital
Sponsor: Astellas Pharma US
Topic: Cresemba (isavuconazonium sulfate): Clinical Efficacy and Safety in the Treatment of Invasive Aspergillosis and Invasive Mucormycosis in Adults
Dr. Michael Nailor, a clinical specialist in infectious disease, from Hartford Hospital was the guest speaker at the New York City Society of Health-System Pharmacists (NYCSHP) last networking dinner of the year. The event was held in the Upper West Side at Scaletta Ristorante.
Dr. Nailor presented on “Cresemba (isavuconazonium sulfate): Clinical Efficacy and Safety in the Treatment of Invasive Aspergillosis and Invasive Mucormycosis in Adults.” He provided the audience with interesting data obtained from two clinical trials, one compared Cresemba to Voriconazole for the treatment of an invasive fungal disease caused by Aspergillus spp.
Aspergillosis is an infection of the lungs (~95%), which may spread to the brain. Some of the risk factors specifically mentioned are hematologic malignancy, allogeneic hematopoietic stem cell transplantation (HSCT), neutropenia, corticosteroid use, and t-cell immunosuppression use.
The second clinical trial did a comparison study testing Cresemba to Voriconazole for the treatment of a life-threatening fungal infection called Mucormycosis, caused primarly by Rhizopus spp. Risk factors were similar to Aspergillosis but also include patients with diabetic ketoacidosis.
Dr. Nailor did a wonderful presentation explaining the clinical and safety data this evening. Thanks to Astellas Pharma for sponsoring a successful networking event!
Our president, Dr. Yi Guo ended the evening with announcements about the organization’s upcoming events. Check your emails for updates!
Written by: Gretchen Marcelino